Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 54.26

-1.5%

10:51 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: zeta1961 who wrote (10694)	2/27/2004 4:58:49 PM
From: Biomaven	Read Replies (2) of 52153

zeta, Sorry to hear about your late husband and glio. It's always worth remembering that the true "bottom line" in biotech should ultimately be measured in helping people, not making money. I have followed Oncolytics intermittently, from even before they were spun out of Synsorb (or whatever it's parent was called - it's been a few years). I'll take another look. This is a nice introductory article on reovirus and cancer that you likely already have seen: J Clin Invest, April 2000, Volume 105, Number 8, 1035-1038 Copyright ©2000 by the American Society for Clinical Investigation Reovirus as a novel oncolytic agent Kara L. Norman and Patrick W.K. Lee jci.org Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next